Loprazolam is an imidazobenzodiazepine with anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties. It is indicated for the short-term treatment of insomnia including difficulty in falling asleep and/or frequent nocturnal awakenings. Loprazolam is recommended as a short-term therapy only, due to adverse events associated with the drug including dependence and withdrawal symptoms. It is a positive modulator of GABA-A receptor that enhances the inhibitory neurotransmission. It is not an FDA-approved drug.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Loprazolam. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Loprazolam. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Loprazolam. |
| Hydrocodone | Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Loprazolam. |
| Magnesium sulfate | The therapeutic efficacy of Loprazolam can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Loprazolam may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Loprazolam. |
| Mirtazapine | Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Loprazolam. |
| Orphenadrine | Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Loprazolam. |
| Pramipexole | Loprazolam may increase the sedative activities of Pramipexole. |
| Ropinirole | Loprazolam may increase the sedative activities of Ropinirole. |
| Rotigotine | Loprazolam may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Loprazolam. |
| Suvorexant | Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Loprazolam. |
| Thalidomide | Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Clozapine | The risk or severity of adverse effects can be increased when Loprazolam is combined with Clozapine. |
| Methadone | Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone. |
| Olanzapine | The risk or severity of adverse effects can be increased when Loprazolam is combined with Olanzapine. |
| Phenytoin | The serum concentration of Phenytoin can be increased when it is combined with Loprazolam. |
| Fosphenytoin | The serum concentration of Fosphenytoin can be increased when it is combined with Loprazolam. |
| Sodium oxybate | Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Teduglutide | The serum concentration of Loprazolam can be increased when it is combined with Teduglutide. |
| Yohimbine | The therapeutic efficacy of Loprazolam can be increased when used in combination with Yohimbine. |
| Flumazenil | Flumazenil may decrease the sedative activities of Loprazolam. |
| Ethanol | Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Loprazolam. |
| Zimelidine | The risk or severity of adverse effects can be increased when Loprazolam is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Loprazolam is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Loprazolam is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Loprazolam is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Loprazolam is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Loprazolam is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Loprazolam is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Loprazolam is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Loprazolam is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Loprazolam is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Loprazolam is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Loprazolam is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Loprazolam is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Loprazolam is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Loprazolam. |
| Indalpine | The risk or severity of adverse effects can be increased when Loprazolam is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Loprazolam is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Loprazolam is combined with Alaproclate. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Loprazolam. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Loprazolam. |
| Zopiclone | The risk or severity of adverse effects can be increased when Loprazolam is combined with Zopiclone. |
| Caffeine | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Caffeine. |
| Theophylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Theophylline. |
| Dyphylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Dyphylline. |
| Pentoxifylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Pentoxifylline. |
| Mercaptopurine | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Mercaptopurine. |
| Aminophylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Aminophylline. |
| Oxtriphylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Oxtriphylline. |
| Theobromine | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Theobromine. |
| Fenethylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Fenethylline. |
| 8-azaguanine | The therapeutic efficacy of Loprazolam can be decreased when used in combination with 8-azaguanine. |
| 7,9-Dimethylguanine | The therapeutic efficacy of Loprazolam can be decreased when used in combination with 7,9-Dimethylguanine. |
| Xanthine | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Xanthine. |
| 7-Deazaguanine | The therapeutic efficacy of Loprazolam can be decreased when used in combination with 7-Deazaguanine. |
| Guanine | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Guanine. |
| 9-Methylguanine | The therapeutic efficacy of Loprazolam can be decreased when used in combination with 9-Methylguanine. |
| Peldesine | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Peldesine. |
| Hypoxanthine | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Hypoxanthine. |
| 9-Deazaguanine | The therapeutic efficacy of Loprazolam can be decreased when used in combination with 9-Deazaguanine. |
| Propentofylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Propentofylline. |
| Valomaciclovir | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Valomaciclovir. |
| 3-isobutyl-1-methyl-7H-xanthine | The therapeutic efficacy of Loprazolam can be decreased when used in combination with 3-isobutyl-1-methyl-7H-xanthine. |
| Uric acid | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Uric acid. |
| Doxofylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Doxofylline. |
| 6-O-benzylguanine | The therapeutic efficacy of Loprazolam can be decreased when used in combination with 6-O-benzylguanine. |
| Lisofylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Lisofylline. |
| Lobucavir | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Lobucavir. |
| Cafedrine | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Cafedrine. |
| Theodrenaline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Theodrenaline. |
| Bamifylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Bamifylline. |
| Proxyphylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Proxyphylline. |
| Acefylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Acefylline. |
| Etamiphylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Etamiphylline. |
| Pentifylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Pentifylline. |
| Bufylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Bufylline. |
| Bromotheophylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Bromotheophylline. |
| Furafylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with Furafylline. |
| 8-chlorotheophylline | The therapeutic efficacy of Loprazolam can be decreased when used in combination with 8-chlorotheophylline. |
| PCS-499 | The therapeutic efficacy of Loprazolam can be decreased when used in combination with PCS-499. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Loprazolam. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Loprazolam. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Loprazolam. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Loprazolam. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Loprazolam. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Loprazolam. |